Connectyx Technologies
Curative Biotechnology focuses on identifying, acquiring, and developing disease-modifying therapeutic drug candidates, especially for rare diseases. The company aims to build a pipeline of first-in-class drugs with accelerated development pathways to address unmet medical needs. It has a diverse pipeline including programs for degenerative eye disease, neuro-oncology, infectious disease, and treatments for rabies and glioblastoma. The company emphasizes innovative treatments and strategic licensing from reputable institutions like NIH and NCI, with a mission to provide therapeutic options for all patients.
Industries
Nr. of Employees
small (1-50)
Products
Antibody-drug conjugate targeting tumor antigen for neuro-oncology
A licensed fully human monoclonal antibody conjugated to a high-potency cytotoxic payload developed for focal delivery to antigen-positive brain tumors as a disease-modifying therapy.
Immunostimulatory therapy for late-stage symptomatic infectious disease
A licensed immunostimulatory therapeutic platform developed to augment host immune responses in patients with advanced symptomatic infections where standard prophylactic vaccines are ineffective.
Repurposed topical ocular formulation of an approved small molecule for retinal disease
A reformulated approved small molecule designed for topical ocular administration to deliver therapeutic exposure to the retinal pigment epithelium for degenerative retinal indications.
Adjuvant-enhanced protein vaccine candidates for immunocompromised populations
Development of protein antigens combined with an immunostimulatory adjuvant intended to improve vaccine responses in patients with impaired immunity.
Antibody-drug conjugate targeting tumor antigen for neuro-oncology
A licensed fully human monoclonal antibody conjugated to a high-potency cytotoxic payload developed for focal delivery to antigen-positive brain tumors as a disease-modifying therapy.
Immunostimulatory therapy for late-stage symptomatic infectious disease
A licensed immunostimulatory therapeutic platform developed to augment host immune responses in patients with advanced symptomatic infections where standard prophylactic vaccines are ineffective.
Repurposed topical ocular formulation of an approved small molecule for retinal disease
A reformulated approved small molecule designed for topical ocular administration to deliver therapeutic exposure to the retinal pigment epithelium for degenerative retinal indications.
Adjuvant-enhanced protein vaccine candidates for immunocompromised populations
Development of protein antigens combined with an immunostimulatory adjuvant intended to improve vaccine responses in patients with impaired immunity.
Services
Negotiation and execution of exclusive licenses and strategic development agreements with academic institutes and biotech partners to acquire rights to therapeutic assets and collaborate on clinical development.
Negotiation and execution of exclusive licenses and strategic development agreements with academic institutes and biotech partners to acquire rights to therapeutic assets and collaborate on clinical development.
Expertise Areas
- Clinical trial management and adaptive trial design
- Preclinical development and IND-enabling studies
- Formulation development and CMC for topical ocular delivery
- Antibody-drug conjugate and monoclonal antibody development
Key Technologies
- Monoclonal antibodies
- Antibody-drug conjugates (ADC)
- High-potency cytotoxic payloads (PBD-class and analogous chemotypes)
- Topical ocular drug delivery formulations
News & Updates
Announcement of Dr. Theresa Heah's nomination to the board, highlighting her expertise and role in guiding the company's strategic direction.
Addition of industry veterans Dr. Ronald Bordens and Dr. Michael Grace to the management team to guide clinical development, regulatory, and scientific strategies.
Acquisition of worldwide rights from Mid-Atlantic BioTherapeutics for the development of IMT504, a novel immunotherapy for rabies, including orphan drug designation.
An article discussing the importance of execution in clinical development and the connection between scientific theory and real-world application.
A reflection on the progress in treating glioblastoma and the company's first-in-class antibody drug conjugate for brain tumors.
Discussion on licensing a reformulation of Metformin for wet AMD, emphasizing the strategy of targeting larger patient populations first.
Announcement of Dr. Theresa Heah's nomination to the board, highlighting her expertise and role in guiding the company's strategic direction.
Addition of industry veterans Dr. Ronald Bordens and Dr. Michael Grace to the management team to guide clinical development, regulatory, and scientific strategies.
Acquisition of worldwide rights from Mid-Atlantic BioTherapeutics for the development of IMT504, a novel immunotherapy for rabies, including orphan drug designation.
An article discussing the importance of execution in clinical development and the connection between scientific theory and real-world application.
A reflection on the progress in treating glioblastoma and the company's first-in-class antibody drug conjugate for brain tumors.
Discussion on licensing a reformulation of Metformin for wet AMD, emphasizing the strategy of targeting larger patient populations first.